Keep up with our latest news, and connect with us on social media.


Epic Bio to Participate in the Solebury / BMO Fall Private Company Showcase

SOUTH SAN FRANCISCO, Calif. — October 6, 2022 — EPIC BIO, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCas protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York. The event is co-hosted by BMO Capital Markets and Goodwin Law.

Chief Executive Officer, Amber Salzman, Ph.D., is scheduled to present on October 13 at 2:40 pm ET. The Company will be taking meetings with select investors and analysts.

Interested parties can register for the event on the Solebury website, found here.

About Epic Bio

Epic Bio is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through its exclusive license of CasMINI, the most compact Cas DNA-binding protein to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypercholesterolemia (HeFH), as well as other programs. The company is financially backed by Horizons Ventures and other leading investors. Visit for more information or follow us on Twitter and LinkedIn.

Investor Contact

Jessica Vo
Gilmartin Group, LLC

Media Contact

Lisa Raffensperger
Ten Bridge Communications

The latest from Epic

16 Nov

"The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: "

7 Nov

"We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: "

31 Oct

"@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics #CellTherapy #Cancer "